Market Intelligence, Clinical Progress, and High-Purity Reagents for Immunotherapy and Multiple Myeloma Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SLAMF6 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SLAMF6 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed for native glycosylation. |
View SLAMF6 Products |
| Gene Delivery | SLAMF6 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cell-based functional assays. |
View SLAMF6 Products |
| Benchmark Ab | Anti-SLAMF6 Recombinant Antibody Recombinant positive control derived from benchmark clinical-stage sequences. |
View SLAMF6 Products |
| Validator | SLAMF6 siRNA Set For target knockdown verification and specificity validation. |
View SLAMF6 Products |
| Related Target A | SLAMF7 (CS1) Synergistic SLAM family target highly co-expressed in multiple myeloma; essential for cross-reactivity and combination therapy profiling. |
View SLAMF7 Products |
| Related Target B | CD3E Critical T-cell engager partner for bispecific antibody (SLAMF6 x CD3) development. |
View CD3E Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Homophilic Binding Interference | Sequence-verified, high-purity SLAMF6 ECD-Fc proteins ensure accurate homophilic interaction (SLAMF6-SLAMF6) blocking assays. |
| SLAM Subfamily Cross-Reactivity | Comprehensive SLAM family panel (SLAMF1 to SLAMF9) available for high-throughput selectivity screening. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay calibration. |
| False Positives | Validated siRNA sets included for target-specific knockdown verification. |
Live SLAMF6 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SLAMF6 therapeutics is intensifying, with major players shifting focus from traditional mAbs to bispecific antibodies and CAR-NK/CAR-T cell therapies. As first-generation therapies targeting hematological malignancies reach clinical assessment, the next wave of R&D is targeting SLAMF6 homophilic interaction blockade to reverse T-cell exhaustion in solid tumors and multiple myeloma.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Bispecific Antibodies (e.g., SLAMF6 x CD3) | Biotech Innovators, Academic Centers | Multiple Myeloma, T-cell Lymphoma | Heterodimer Validation (Need High-Purity SLAMF6 and CD3E target proteins) |
| CAR-T / CAR-NK Cell Therapies | Cell Therapy Developers | Refractory Hematological Malignancies | Target Cell Line Construction (Need Lentivirus for Stable SLAMF6 Expression) |
| Monoclonal Antibodies (mAbs) | Global Biopharma Partners | Autoimmune Diseases, Oncology | Homophilic Blocking Assay (Need Native Glycosylated ECD-Fc Proteins) |